A Blood Test for Alzheimer’s Disease?
Summary
The U.S. FDA has approved Lumipulse, a blood test that detects Alzheimer's disease by measuring two proteins—pTau217 and ß-Amyloid 1-42—in plasma. This test offers a less invasive and more accessible alternative to traditional methods, such as PET scans and spinal taps. In clinical studies, Lumipulse demonstrated a 91.7% positive predictive value and a 97.3% negative predictive value, indicating high accuracy in confirming the presence or absence of amyloid plaques associated with Alzheimer's. However, the test is currently not intended for early diagnosis in healthy individuals without cognitive impairment.
Psychology Today
Read the Full Article
The dedicated team at Newsletter Station has provided this summary for your convenience.
Unlock the Power of Email Marketing
Harness the potential of email marketing with Newsletter Station. Reach your target audience, drive conversions, and achieve your business goals.
|
|
|
